SCHEMBL8009626

SCHEMBL8009626

CCCc1c(OC)cc(OC)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.44
▸ HMGCR P04035 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ CYP3A4 P08684 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ CALM1 P0DP23 1/20 0.40
▸ HIF1A Q16665 1/20 0.39
▸ EPAS1 Q99814 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115040 0.86 HMGCR (0.50) HMGCRCYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL6312974 0.86 CALM1 (0.57) ALDH1A1CYP3A4CALM1
SCHEMBL27987105 0.84 ALOX5 (0.56) CA1CA2CYP3A4
SCHEMBL919069 0.83 CYP1A1 (0.61) CYP1A2ALDH1A1CYP3A4MAPK1
SCHEMBL930954 0.83 CYP1A1 (0.61) CYP1A2ALDH1A1CYP3A4MAPK1
SCHEMBL9145125 0.82 CYP1A2 (0.46) CYP1A2HMGCRALDH1A1CA1CA2
SCHEMBL12844405 0.82 ACHE (0.50) HMGCRALDH1A1PDE3BPDE3ACYP3A4
SCHEMBL6450693 0.82 PTGS2 (0.37) CYP1A2HMGCRALDH1A1PDE3BPDE3A
SCHEMBL5185794 0.81 ALDH1A1 (0.48) CYP1A2ALDH1A1CA1CA2CA12
SCHEMBL918847 0.80 PTGS2 (0.59) HMGCRALDH1A1CA2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-12-18 — — US disclosed
US-20070117797-A1 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2007-05-24 — — US disclosed
US-6057315-A INHIBIT BACTERIAL SIGNAL TRANSDUCTION IN MAMMALS WARNER-LAMBERTT COMPANY (US) 2000-05-02 — — US disclosed
EP-0942912-A1 ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-09-22 — — EP disclosed
WO-1998025932-A1 ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-06-18 — — WO disclosed
US-4810792-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1989-03-07 — — US disclosed
US-4788201-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-11-29 — — US disclosed
EP-0275962-A2 3-Methylenespiro [benzofuran-piperidines], intermediates and a process for the preparation thereof, and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-07-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117797-A1 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity CCR7, ACKR3, CCR2 CYP1A2 2461/4885HMGCR 1519/4885ALDH1A1 1954/4885
US-20080312164-A1 ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME GGCT, GSTK1, GCLC CYP1A2 3345/4885HMGCR 1982/4885ALDH1A1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback